Broadcom: Anthropic Financing Risk Is Priced Too High, Buy

Broadcom is rated Buy with a $450 price target, implying approximately 25% upside; the analyst argues the market overstates risks tied to a $29B deficiency guarantee and a $42B convertible facility. The thesis cites robust cash flow and capped exposures, alongside AI revenue targeted at $230B in FY2028 and estimated EPS of $30. Valuation is described as attractive at 20x FY2027 and 12x FY2028 multiples.

Analysis

The key underwriting question is not whether the stated customer-support obligations are “capped,” but whether the cap meaningfully limits Broadcom’s cash exposure in a correlated AI-demand downturn. If a major customer’s funding or deployment schedule slips, guarantee calls and delayed chip/networking revenue could arrive together; strong current cash generation would cushion, not remove, that liquidity and multiple risk. The financing terms, counterparties, triggers, and overlap with committed purchases therefore matter more than the headline amounts.

The bullish case has asymmetric upside only if AI revenue estimates convert into shipped systems and cash collection. Custom silicon and networking demand may benefit Broadcom even if accelerator spending rotates among suppliers, but hyperscaler concentration leaves the company exposed to a small number of capital-budget decisions. Nvidia and Marvell are relevant competitive checks: customer substitution or in-house design changes could weaken Broadcom’s expected content, while continued spending can support multiple semiconductor suppliers.

Near term, analyst enthusiasm is unlikely to be a durable catalyst on its own. Over 1–3 months, watch company guidance, customer commitments, and disclosure clarifying contingent exposure and cash conversion. Over 6–18 months, the central test is whether AI growth and earnings delivery validate the out-year estimates; the apparent low forward multiple is not a margin of safety if those estimates are revised down. Contrarian risk: investors may be treating financing exposure as a binary solvency concern when it may be manageable, but the opposite error is discounting correlated downside because the obligations are described as capped.

Key Decisions for Investors

• Consider a staged, modest long in AVGO rather than buying the full position on the analyst call; add only after guidance and cash conversion support the earnings trajectory. The setup is attractive if estimates hold, but the supplied material does not independently establish the forecast.
• Before sizing, verify the guarantee’s call conditions, counterparties, duration, collateral or recourse, and how the convertible facility interacts with customer commitments. Treat material ambiguity or adverse terms as a reason to defer, not as a reason to assume the exposure is harmless.
• Use the next earnings update and any financing disclosures as 1–3 month catalysts. Reassess or cut the thesis if AI guidance is reduced, cash conversion weakens alongside receivables or customer financing exposure, or management cannot reconcile contingent obligations with expected liquidity.
• Avoid treating the quoted forward multiples as proof of cheapness: track estimate revisions and actual AI-related revenue delivery over the next 6–18 months. If growth expectations remain intact while financing concerns prove bounded, the derating may reverse; if estimates fall, multiple support can disappear quickly.